☰

Malcolm A. Leissring, Ph.D. - Publications

Affiliations: 
2000 University of California, Irvine, Irvine, CA 
Tree Info Grants Similar researchers PubMed Report error

40 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2024 Terron HM, Parikh SJ, Abdul-Hay SO, Sahara T, Kang D, Dickson DW, Saftig P, LaFerla FM, Lane S, Leissring MA. Prominent tauopathy and intracellular β-amyloid accumulation triggered by genetic deletion of cathepsin D: implications for Alzheimer disease pathogenesis. Alzheimer's Research & Therapy. 16: 70. PMID 38575959 DOI: 10.1186/s13195-024-01443-6  0.515
2023 Terron HM, Parikh SJ, Abdul-Hay SO, Sahara T, Kang D, Dickson DW, Saftig P, LaFerla FM, Lane S, Leissring MA. Prominent tauopathy and intracellular β-amyloid accumulation triggered by genetic deletion of cathepsin D: Implications for Alzheimer disease pathogenesis. Research Square. PMID 37961253 DOI: 10.21203/rs.3.rs-3464352/v1  0.515
2023 Terron HM, Maranan DS, Burgard LA, LaFerla FM, Lane S, Leissring MA. A Dual-Function "TRE-Lox" System for Genetic Deletion or Reversible, Titratable, and Near-Complete Downregulation of Cathepsin D. International Journal of Molecular Sciences. 24. PMID 37047718 DOI: 10.3390/ijms24076745  0.429
2020 Suire CN, Abdul-Hay SO, Sahara T, Kang D, Brizuela MK, Saftig P, Dickson DW, Rosenberry TL, Leissring MA. Cathepsin D regulates cerebral Aβ42/40 ratios via differential degradation of Aβ42 and Aβ40. Alzheimer's Research & Therapy. 12: 80. PMID 32631408 DOI: 10.1186/S13195-020-00649-8  0.38
2019 Fernandez-Diaz CM, Merino B, Lopez-Acosta JF, Cidad P, de la Fuente MA, Lobaton CD, Moreno A, Leissring MA, Perdomo G, Cozar-Castellano I. Pancreatic beta-cell-specific deletion of insulin-degrading enzyme leads to dysregulated insulin secretion and beta-cell functional immaturity. American Journal of Physiology. Endocrinology and Metabolism. PMID 31479304 DOI: 10.1152/Ajpendo.00040.2019  0.309
2016 Hogan MF, Meier DT, Zraika S, Templin AT, Mellati M, Hull RL, Leissring MA, Kahn SE. Inhibition of Insulin-Degrading Enzyme Does Not Increase Islet Amyloid Deposition In Vitro. Endocrinology. en20161410. PMID 27404391 DOI: 10.1210/En.2016-1410  0.35
2015 Li H, Zhu H, Wallack M, Mwamburi M, Abdul-Hay SO, Leissring MA, Qiu WQ. Age and Its Association with Low Insulin and High Amyloid-β Peptides in Blood. Journal of Alzheimer's Disease : Jad. PMID 26444783 DOI: 10.3233/Jad-150428  0.349
2014 Leissring MA. Aβ degradation-the inside story. Frontiers in Aging Neuroscience. 6: 229. PMID 25206334 DOI: 10.3389/Fnagi.2014.00229  0.35
2013 Leissring MA, Turner AJ. Regulation of distinct pools of amyloid β-protein by multiple cellular proteases. Alzheimer's Research & Therapy. 5: 37. PMID 23953275 DOI: 10.1186/Alzrt194  0.405
2013 Abdul-Hay SO, Lane AL, Caulfield TR, Claussin C, Bertrand J, Masson A, Choudhry S, Fauq AH, Maharvi GM, Leissring MA. Optimization of peptide hydroxamate inhibitors of insulin-degrading enzyme reveals marked substrate-selectivity. Journal of Medicinal Chemistry. 56: 2246-55. PMID 23437776 DOI: 10.1021/Jm301280P  0.308
2012 Abdul-Hay SO, Sahara T, McBride M, Kang D, Leissring MA. Identification of BACE2 as an avid ß-amyloid-degrading protease. Molecular Neurodegeneration. 7: 46. PMID 22986058 DOI: 10.1186/1750-1326-7-46  0.37
2012 Liu Z, Zhu H, Fang GG, Walsh K, Mwamburi M, Wolozin B, Abdul-Hay SO, Ikezu T, Leissring MA, Qiu WQ. Characterization of insulin degrading enzyme and other amyloid-β degrading proteases in human serum: a role in Alzheimer's disease? Journal of Alzheimer's Disease : Jad. 29: 329-40. PMID 22232014 DOI: 10.3233/Jad-2011-111472  0.363
2010 DelleDonne A, Miles RJ, Dickson DW, Abdul-Hay SO, Ertekin-Taner N, Leissring MA. P1-292: Correlation between insulin-degrading enzyme levels and neuropathology in control versus Alzheimer brains with and without cerebral amyloid angiopathy Alzheimer's & Dementia. 6: S258-S258. DOI: 10.1016/J.Jalz.2010.05.844  0.328
2009 Cabrol C, Huzarska MA, Dinolfo C, Rodriguez MC, Reinstatler L, Ni J, Yeh LA, Cuny GD, Stein RL, Selkoe DJ, Leissring MA. Small-molecule activators of insulin-degrading enzyme discovered through high-throughput compound screening. Plos One. 4: e5274. PMID 19384407 DOI: 10.1371/Journal.Pone.0005274  0.319
2009 Zhao J, Li L, Leissring MA. Insulin-degrading enzyme is exported via an unconventional protein secretion pathway. Molecular Neurodegeneration. 4: 4. PMID 19144176 DOI: 10.1186/1750-1326-4-4  0.403
2009 Leissring MA, Reinstatler L, Sahara T, Sevlever D, Roman R, Ji Z, Li L, Lu Q, Säftig P, Levites Y, Golde TE, Burgess J, Ertekin-Taner N, Eckman EA. O4-03-07: Cathepsin D knockout mice harbor large and highly selective increases in cerebral Aß42 and tau: Implications for Alzheimer's disease pathogenesis Alzheimer's & Dementia. 5: P155-P156. DOI: 10.1016/J.Jalz.2009.05.537  0.32
2008 Leissring MA. The AbetaCs of Abeta-cleaving proteases. The Journal of Biological Chemistry. 283: 29645-9. PMID 18723506 DOI: 10.1074/Jbc.R800022200  0.391
2008 Neant-Fery M, Garcia-Ordoñez RD, Logan TP, Selkoe DJ, Li L, Reinstatler L, Leissring MA. Molecular basis for the thiol sensitivity of insulin-degrading enzyme. Proceedings of the National Academy of Sciences of the United States of America. 105: 9582-7. PMID 18621727 DOI: 10.1073/Pnas.0801261105  0.346
2008 Betts V, Leissring MA, Dolios G, Wang R, Selkoe DJ, Walsh DM. Aggregation and catabolism of disease-associated intra-Abeta mutations: reduced proteolysis of AbetaA21G by neprilysin. Neurobiology of Disease. 31: 442-50. PMID 18602473 DOI: 10.1016/J.Nbd.2008.06.001  0.381
2007 Im H, Manolopoulou M, Malito E, Shen Y, Zhao J, Neant-Fery M, Sun CY, Meredith SC, Sisodia SS, Leissring MA, Tang WJ. Structure of substrate-free human insulin-degrading enzyme (IDE) and biophysical analysis of ATP-induced conformational switch of IDE. The Journal of Biological Chemistry. 282: 25453-63. PMID 17613531 DOI: 10.1074/Jbc.M701590200  0.326
2007 Kim M, Hersh LB, Leissring MA, Ingelsson M, Matsui T, Farris W, Lu A, Hyman BT, Selkoe DJ, Bertram L, Tanzi RE. Decreased catalytic activity of the insulin-degrading enzyme in chromosome 10-linked Alzheimer disease families. The Journal of Biological Chemistry. 282: 7825-32. PMID 17244626 DOI: 10.1074/Jbc.M609168200  0.364
2006 Leissring MA. Proteolytic degradation of the amyloid beta-protein: the forgotten side of Alzheimer's disease. Current Alzheimer Research. 3: 431-5. PMID 17168642 DOI: 10.2174/156720506779025206  0.305
2006 Betts V, Leissring MA, Selkoe DJ, Walsh DM. P1-391: Monomeric Aβ peptides bearing the Flemish A21G mutation are less readily degraded by neprilysin than wild type Aβ Alzheimer's & Dementia. 2: S212-S213. DOI: 10.1016/J.Jalz.2006.05.769  0.338
2005 Farris W, Leissring MA, Hemming ML, Chang AY, Selkoe DJ. Alternative splicing of human insulin-degrading enzyme yields a novel isoform with a decreased ability to degrade insulin and amyloid beta-protein. Biochemistry. 44: 6513-25. PMID 15850385 DOI: 10.1021/Bi0476578  0.397
2004 Bishop G, Coleman P, Crutcher K, David D, Kinoshita J, LaFerla F, Leissring M, Shepherd J, Therianos S, Wang R, Wilson A, Zhu M. Live discussion: how the other half lives - or the what, how, and where, of the AbetaPP intracellular domain. Journal of Alzheimer's Disease : Jad. 6: 193-9. PMID 15171221 DOI: 10.3233/Jad-2004-6212  0.404
2004 Farris W, Mansourian S, Leissring MA, Eckman EA, Bertram L, Eckman CB, Tanzi RE, Selkoe DJ. Partial loss-of-function mutations in insulin-degrading enzyme that induce diabetes also impair degradation of amyloid beta-protein. The American Journal of Pathology. 164: 1425-34. PMID 15039230 DOI: 10.1016/S0002-9440(10)63229-4  0.305
2004 Akbari Y, Dagher N, Murphy MP, Kozak JA, Hitt B, Oddo S, Tseng B, Golde TE, Cahalan M, Leissring MA, M. LaFerla F. P1-206 Capacitative and non-capacitative Ca2+ entry modulate Aβ levels Neurobiology of Aging. 25: S154-S155. DOI: 10.1016/S0197-4580(04)80519-0  0.684
2003 Leissring MA, Farris W, Chang AY, Walsh DM, Wu X, Sun X, Frosch MP, Selkoe DJ. Enhanced proteolysis of beta-amyloid in APP transgenic mice prevents plaque formation, secondary pathology, and premature death. Neuron. 40: 1087-93. PMID 14687544 DOI: 10.1016/S0896-6273(03)00787-6  0.305
2002 Sugarman MC, Yamasaki TR, Oddo S, Echegoyen JC, Murphy MP, Golde TE, Jannatipour M, Leissring MA, LaFerla FM. Inclusion body myositis-like phenotype induced by transgenic overexpression of beta APP in skeletal muscle. Proceedings of the National Academy of Sciences of the United States of America. 99: 6334-9. PMID 11972038 DOI: 10.1073/Pnas.082545599  0.695
2002 Leissring MA, Murphy MP, Mead TR, Akbari Y, Sugarman MC, Jannatipour M, Anliker B, Müller U, Saftig P, De Strooper B, Wolfe MS, Golde TE, LaFerla FM. A physiologic signaling role for the gamma -secretase-derived intracellular fragment of APP. Proceedings of the National Academy of Sciences of the United States of America. 99: 4697-702. PMID 11917117 DOI: 10.1073/Pnas.072033799  0.731
2001 Leissring MA, LaFerla FM, Callamaras N, Parker I. Subcellular mechanisms of presenilin-mediated enhancement of calcium signaling. Neurobiology of Disease. 8: 469-78. PMID 11442355 DOI: 10.1006/Nbdi.2001.0382  0.591
2001 Marchant JS, Stutzmann GE, Leissring MA, LaFerla FM, Parker I. Multiphoton-evoked color change of DsRed as an optical highlighter for cellular and subcellular labeling. Nature Biotechnology. 19: 645-9. PMID 11433276 DOI: 10.1038/90249  0.463
2000 LaFerla FM, Sugarman MC, Lane TE, Leissring MA. Regional hypomyelination and dysplasia in transgenic mice with astrocyte-directed expression of interferon-gamma. Journal of Molecular Neuroscience : Mn. 15: 45-59. PMID 11211236 DOI: 10.1385/Jmn:15:1:45  0.5
2000 Leissring MA, Yamasaki TR, Wasco W, Buxbaum JD, Parker I, LaFerla FM. Calsenilin reverses presenilin-mediated enhancement of calcium signaling. Proceedings of the National Academy of Sciences of the United States of America. 97: 8590-3. PMID 10900016 DOI: 10.1073/Pnas.97.15.8590  0.744
2000 Leissring MA, Akbari Y, Fanger CM, Cahalan MD, Mattson MP, LaFerla FM. Capacitative calcium entry deficits and elevated luminal calcium content in mutant presenilin-1 knockin mice. The Journal of Cell Biology. 149: 793-8. PMID 10811821 DOI: 10.1083/Jcb.149.4.793  0.725
2000 Mattson MP, LaFerla FM, Chan SL, Leissring MA, Shepel PN, Geiger JD. Calcium signaling in the ER: its role in neuronal plasticity and neurodegenerative disorders. Trends in Neurosciences. 23: 222-9. PMID 10782128 DOI: 10.1016/S0166-2236(00)01548-4  0.54
1999 Leissring MA, Parker I, LaFerla FM. Presenilin-2 mutations modulate amplitude and kinetics of inositol 1, 4,5-trisphosphate-mediated calcium signals. The Journal of Biological Chemistry. 274: 32535-8. PMID 10551803 DOI: 10.1074/Jbc.274.46.32535  0.604
1999 Leissring MA, Paul BA, Parker I, Cotman CW, LaFerla FM. Alzheimer's presenilin-1 mutation potentiates inositol 1,4,5-trisphosphate-mediated calcium signaling in Xenopus oocytes. Journal of Neurochemistry. 72: 1061-8. PMID 10037477 DOI: 10.1046/J.1471-4159.1999.0721061.X  0.598
1998 Leissring MA, Sugarman MC, LaFerla FM. Herpes simplex virus infections and Alzheimer's disease. Implications for drug treatment and immunotherapy. Drugs & Aging. 13: 193-8. PMID 9789723 DOI: 10.2165/00002512-199813030-00002  0.47
1997 Weber LL, Leissring MA, Yang AJ, Glabe CG, Cribbs DH, LaFerla FM. Presenilin-1 immunoreactivity is localized intracellularly in Alzheimer's disease brain, but not detected in amyloid plaques. Experimental Neurology. 143: 37-44. PMID 9000444 DOI: 10.1006/Exnr.1996.6348  0.533
Show low-probability matches.